Published in PLoS One on April 11, 2012
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res (2014) 1.19
A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells. Genome Res (2013) 0.97
Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci (2013) 0.89
Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastasis (2014) 0.81
Gene expression profiling analysis of castration-resistant prostate cancer. Med Sci Monit (2015) 0.80
Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets. PLoS Comput Biol (2015) 0.78
Research Resource: Androgen Receptor Activity Is Regulated Through the Mobilization of Cell Surface Receptor Networks. Mol Endocrinol (2015) 0.76
Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway. PLoS One (2014) 0.75
The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates. Heliyon (2017) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Significance analysis of time course microarray experiments. Proc Natl Acad Sci U S A (2005) 8.65
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 4.51
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Mps1 is a kinetochore-associated kinase essential for the vertebrate mitotic checkpoint. Cell (2001) 3.16
AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol (2001) 2.81
Kinetochore localization of spindle checkpoint proteins: who controls whom? Mol Biol Cell (2004) 2.50
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res (2002) 2.46
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol (2007) 2.09
Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A (2009) 2.04
Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res (2009) 2.04
Androgen receptor as a target in androgen-independent prostate cancer. Urology (2002) 1.91
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res (1999) 1.64
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer (2005) 1.43
Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem (2007) 1.23
A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene (2007) 1.12
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 0.95
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
Genome-wide in situ exon capture for selective resequencing. Nat Genet (2007) 19.97
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell (2007) 18.35
Dicer is essential for mouse development. Nat Genet (2003) 15.87
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev (2006) 15.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Processing of primary microRNAs by the Microprocessor complex. Nature (2004) 14.59
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Crystal structure of Argonaute and its implications for RISC slicer activity. Science (2004) 12.48
MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol (2005) 12.12
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Discovery of functional elements in 12 Drosophila genomes using evolutionary signatures. Nature (2007) 11.66
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev (2006) 11.04
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature (2008) 10.71
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev (2002) 10.71
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature (2006) 9.88
RNA polymerase is poised for activation across the genome. Nat Genet (2007) 9.57
The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science (2007) 9.36
Sorting of small RNAs into Arabidopsis argonaute complexes is directed by the 5' terminal nucleotide. Cell (2008) 9.02
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Small RNAs as guardians of the genome. Cell (2009) 8.88
Characterization of Dicer-deficient murine embryonic stem cells. Proc Natl Acad Sci U S A (2005) 8.35
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
An endogenous small interfering RNA pathway in Drosophila. Nature (2008) 7.88
Developmentally regulated piRNA clusters implicate MILI in transposon control. Science (2007) 7.68
MIWI2 is essential for spermatogenesis and repression of transposons in the mouse male germline. Dev Cell (2007) 7.66
The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev (2002) 7.61
A role for the P-body component GW182 in microRNA function. Nat Cell Biol (2005) 7.54
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol (2003) 6.90
Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol (2005) 6.64
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev (2002) 6.43
Specialized piRNA pathways act in germline and somatic tissues of the Drosophila ovary. Cell (2009) 6.39
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature (2010) 6.37
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice. Mol Cell (2008) 6.35
A role for Piwi and piRNAs in germ cell maintenance and transposon silencing in Zebrafish. Cell (2007) 6.31
A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science (2010) 5.84
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Genome analysis of the platypus reveals unique signatures of evolution. Nature (2008) 5.74
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Alta-Cyclic: a self-optimizing base caller for next-generation sequencing. Nat Methods (2008) 5.70
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell (2009) 5.51
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Cancer proliferation gene discovery through functional genomics. Science (2008) 5.41
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
RNA interference in adult mice. Nature (2002) 5.33
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A (2005) 5.29
A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci U S A (2007) 5.16
Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A (2002) 5.05
An epigenetic role for maternally inherited piRNAs in transposon silencing. Science (2008) 5.05
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Genome-wide localization of the nuclear transport machinery couples transcriptional status and nuclear organization. Cell (2004) 4.95
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
A complex system of small RNAs in the unicellular green alga Chlamydomonas reinhardtii. Genes Dev (2007) 4.95
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Distinct catalytic and non-catalytic roles of ARGONAUTE4 in RNA-directed DNA methylation. Nature (2006) 4.68
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
The CRISPR system: small RNA-guided defense in bacteria and archaea. Mol Cell (2010) 4.60
Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell (2009) 4.57
Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 4.51
Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing. Nat Protoc (2009) 4.45
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Systematic discovery and characterization of fly microRNAs using 12 Drosophila genomes. Genome Res (2007) 4.28
Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet (2010) 4.27